Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally. Mavacamten is being developed to treat obstructive and non-obstructive forms of a condition called hypertrophic cardiomyopathy - estimated to affect one in every 500 people globally. For more information you can review our Terms of Service and Cookie Policy. MyoKardia expects to submit marketing application to the U.S. health regulator for obstructive HCM in the first quarter of 2021 after the drug met the main goal of a late-stage study.
Its time to submit the application was postponed by 4 years.
( z0 postpone :ARG1 ( z1 time :time-of ( z2 submit :ARG1 ( z3 apply ) ) ) :ARG2 ( z4 temporal-quantity :quant 4 :unit ( z5 year ) ) )
(z0 / postpone-01
    :ARG1 (z1 / time
              :time-of (z2 / submit-01
                           :ARG1 (z3 / apply-01)))
    :ARG2 (z4 / temporal-quantity
              :quant 4
              :unit (z5 / year)))
Its time to submit the application was postponed by 4 years .
z1 :time-of z2
z2 :ARG1 z3
z0 :ARG1 z1
z4 :quant 0
z0 :ARG2 z4
z4 :unit z5